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Abstract
Background: Preterm prelabour rupture of the membranes (PPROM) is an important clinical
problem and a dilemma for the gynaecologist. On the one hand, awaiting spontaneous labour
increases the probability of infectious disease for both mother and child, whereas on the other
hand induction of labour leads to preterm birth with an increase in neonatal morbidity (e.g.,
respiratory distress syndrome (RDS)) and a possible rise in the number of instrumental deliveries.
Methods/Design: We aim to determine the effectiveness and cost-effectiveness of immediate
delivery after PPROM in near term gestation compared to expectant management. Pregnant
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until 37+0 weeks will be included in a multicentre prospective randomised controlled trial. We will
compare early delivery with expectant monitoring.
The primary outcome of this study is neonatal sepsis. Secondary outcome measures are maternal
morbidity (chorioamnionitis, puerperal sepsis) and neonatal disease, instrumental delivery rate,
maternal quality of life, maternal preferences and costs. We anticipate that a reduction of neonatal
infection from 7.5% to 2.5% after induction will outweigh an increase in RDS and additional costs
due to admission of the child due to prematurity. Under these assumptions, we aim to randomly
allocate 520 women to two groups of 260 women each. Analysis will be by intention to treat.
Additionally a cost-effectiveness analysis will be performed to evaluate if the cost related to early
delivery will outweigh those of expectant management. Long term outcomes will be evaluated using
modelling.
Discussion: This trial will provide evidence as to whether induction of labour after preterm
prelabour rupture of membranes is an effective and cost-effective strategy to reduce the risk of
neonatal sepsis.
Controlled clinical trial register: ISRCTN29313500
Background
Preterm prelabour rupture of the membranes (PPROM) is
an important clinical problem and a dilemma for the
gynaecologist. On the one hand, awaiting spontaneous
labour may lead to an increase in infectious disease for
both mother and child, whereas on the other hand induc-
tion of labour leads to preterm birth with an increase in
neonatal morbidity (e.g., respiratory distress syndrome
(RDS)) and a possible rise in the number of instrumental
deliveries.
The estimated incidence of PPROM between 34 and 37
weeks of gestation is 1.5%, which equals about 3.000
cases per year in the Netherlands. The incidence of RDS is
estimated to decrease from 15% at 34 weeks to below 1%
at 37 weeks' gestation [1]. On the other hand, the proba-
bility that sepsis occurs increases when expectant manage-
ment is advocated. In case the child is born immediately
after PPROM, the risk of sepsis is 2.5%, whereas it
increases to 7.5% in case of expectant management [2,3].
Until now, management of PPROM between 34 and 37
weeks' gestation varies in the Netherlands. In the guide-
line of the Dutch Society of Obstetrics and Gynaecology
(NVOG) expectant management is advocated if the gesta-
tional age is under 35 weeks [4]. Beyond 35 weeks, the
guideline makes no clear recommendation, and the deci-
sion for either induction of labour or expectant manage-
ment (either in hospital or with monitoring at home), is
left to local protocols. International guidelines do not
make a clear statement either [5,6].
This dilemma can be explained by a lack of good clinical
evidence. As a consequence, the course of action on this
subject varies in the Netherlands. Data from the Dutch
National Delivery Registration indicate that in about 70%
of the patients an expectant management has been prac-
tised, whereas in about 30% of the cases labour was
induced preterm. The current national registrations pro-
vide no insight in the reason for induction in the latter
group, as some inductions might have been performed
following signs of intra-uterine infection.
In view of the lack of good clinical evidence and the prac-
tice variation described above, a randomised clinical trial
comparing induction of labour and expectant monitoring
in patients with PPROM is needed urgently.
We are aware of four small studies that have been per-
formed to discern between the treatment policies for
PPROM [7-10]. Naef et al. compared induction of labour
versus expectant management in a group of 120 patients
with PPROM occurring at 34 until 37 weeks gestation and
found a non-significant decrease of chorioamnionitis in
the induction group without a significant difference in
neonatal morbidity (including RDS) between both
groups [7]. Patients with PPROM managed expectantly
were hospitalised significantly longer. More babies of the
expectant group were diagnosed with sepsis and admitted
to the neonatal ward for a longer duration. This difference
did not reach the level of significance due to the small
number of the study.
Cox et al. compared maternal and neonatal outcome in a
group of 129 patients with PPROM occurring at 30 until
34 weeks' gestation after randomization between expect-
ant management and induction of labour [8]. Again, no
significant differences in neonatal outcome were noted.
However, a non-significant decrease in sepsis was seen in
the induction group. Also, chorioamnionitis wasPage 2 of 6
(page number not for citation purposes)
BMC Pregnancy and Childbirth 2007, 7:11 http://www.biomedcentral.com/1471-2393/7/11observed less frequently in the latter group. Mercer et al.
performed a similar study of 93 patients with PPROM in
a different age category (32 until 36 weeks' gestation) and
observed similar differences as Cox and co-workers [9].
Spinnato et al. found no difference in neonatal outcome
between expected management and prompt delivery in 47
patients with premature rupture of membranes (before 36
weeks) with documented foetal pulmonary maturity [10].
However, they demonstrated an increased risk of maternal
infection when expectant management was applied.
These studies show a trend towards better neonatal out-
come in the induction group, but in these small samples
differences were not statistically significant. Even meta-
analysis did not generate sufficient statistical power [11].
In view of the practice variation described above and the
lack of sound clinical evidence for this clinical dilemma,
we have recently started a multicentre trial.
Methods/Design
Aims
The aim of this study is to systematically compare early
initiation of delivery and expectant management in case
of preterm prelabour rupture of membranes in terms of
neonatal sepsis and RDS, maternal health, health-related
quality-of-life and costs. As it is impossible to blind the
healthcare workers and patients involved for the strategy
of allocation, we will use a multicentre randomised con-
trolled open label trial to assess the effects of initiation of
delivery or expectant management on neonatal outcome.
This study is set in the Dutch Obstetric Consortium, a col-
laboration of obstetric clinics in the Netherlands. Approx-
imately 40 clinics, including academic hospitals, non-
academic teaching hospitals and non-teaching hospitals
will participate in this trial.
Participants/eligibility criteria
Women presenting with preterm prelabour rupture of the
foetal membranes between 34+0 and 37+0 weeks' gestation
who have not delivered within 24 hours after rupture of
the foetal membranes are eligible for participation in the
PPROMEXIL-trial. Even so women presenting with pre-
term prelabour rupture of foetal membranes after 26+0
weeks gestation who have not delivered at 34+0 weeks of
gestation are eligible for participation. Both women with
singleton and women with multiple gestations can be
included. Women with a child in breech presentation can
also be included, and both an elective caesarean section
and a vaginal delivery are allowed for these women.
Women with monochorionic multiple pregnancies,
abnormal (non-reassuring) cardiotocogram (CTG),
meconium stained amniotic fluid, signs of intrauterine
infection, major foetal anomalies, labour, HELLP syn-
drome or severe pre-eclampsia, will not be included in the
study.
Procedures, recruitment, randomisation and collection of 
baseline data
The research nurse and/or the staff of participating hospi-
tals will identify eligible women. After the subject has
given informed consent for participation in the study, she
will be randomised to either a policy that aims at termina-
tion of the pregnancy (intervention group) or a policy that
aims at expectant management for spontaneous delivery
(expectant group). Once the subject data have been
entered anonymously in a web-based database, either a
staff member or the research nurse will randomise using
an internet based procedure. Randomisation will be 1:1
for intervention or expectant management and stratified
for centre and previous delivery.
At study entry baseline demographics, past obstetric and
medical history will be recorded. Maternal temperature is
measured and baseline blood samples are taken. From all
participating women a vaginal swab is collected either at
admission to the hospital with premature ruptured mem-
branes or at study entry. Antibiotics are given in accord-
ance to local policy. All women will undergo an
ultrasound examination at study entry. If a previous ultra-
sound examination was done within a fortnight before
study entry in the same hospital, which revealed no
abnormal results, these outcomes may be recorded at
study entry. Women fill out a baseline quality of life ques-
tionnaire containing EuroQoL, 5D3L, HADS, SF-36 and
background questions. They are also asked on their prior
intervention preference.
At local centres data-collection will be the responsibility
of the local research coordinator and the regional research
nurses. The data for this study must be collected, coded
and processed with adequate precautions to ensure
patient confidentially.
Interventions
Intervention group
Women randomised for intervention will be planned for
induction of labour or elective caesarean section as soon
as reasonable after randomisation. Because of the fact that
randomisation will take place preferable 24 hours after
rupture of the foetal membranes it is imaginable that due
to logistic reasons induction of labour is postponed until
the following morning, but within 12 hours after ran-
domisation. Induction of labour will take place according
to local policy. In case of breech presentation, a primary
caesarean section is allowed based on the preference of
both the patient and the gynaecologist. Similarly in case
of a dichorionic twin an elective caesarean section may bePage 3 of 6
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the first twin.
Expectant group
Women randomised for expectant management will be
treated according to local policy. This might be either in
an outpatient or inpatient setting. If a patient in the
expectant group reaches 37+0 weeks of gestation age,
induction of labour is performed according to local pol-
icy. Whenever a patient with an indication for elective cae-
sarean section will be allocated to expectant management
the caesarean section will be performed as soon as labour
commences.
Follow up of women and infants
Information is obtained on the condition, weight, length
and neonatal morbidity and mortality from the infant and
maternal records as well as maternal complications and
length of stay. If applicable, neonatal antibiotic treatment,
blood samples and cultures are recorded. In case of admit-
tance of the baby to the neonatal intensive care, high care
or medium care unit, details of this admittance are also
documented. The placenta will be sent for histological
examination on chorioamnionitis and funisitis.
Six weeks and six months post partum neonatal length,
weight, neurological disabilities, physical disabilities and
maternal disabilities will be recorded. Patients will be
asked to fill out follow-up quality of life questionnaires
including EuroQoL, 5D3L, HADS, SF-36, SCL-90 also
concerning the development of the child. Women are also
asked to (re)state their intervention preference. Long-term
follow up of the children is not yet planned, and depends
on future funding.
Outcome measures
The primary outcome measure is neonatal sepsis. Neona-
tal sepsis is defined as a positive blood culture, biochem-
ical infection parameters (C-reactive protein (CRP) above
20 mg/l) or clinical signs of infection (apnoea, fever,
intolerance for feeding, respiratory distress and/or
haemodynamic instability) with positive surface cultures.
An independent panel of paediatricians will define
between proven or probable sepsis without knowledge of
the outcome data.
Secondary infant outcome measures are respiratory dis-
tress syndrome (RDS) (defined according to the Organ
dysfunction criteria), transient tachypnoea of the new-
born asphyxia (defined according to Sarnat), pneumotho-
rax/pneumomediastinum, late onset sepsis,
hypoglycaemia, meconium aspiration syndrome, necro-
tizing enterocolitis (NEC) (defined according to Bell stag-
ing), hyperbilirubinemia, in, traventricular haemorrhage,
periventricular leucomalacia, convulsions, other neuro-
logical abnormalities and congenital abnormalities [12-
14].
Secondary maternal outcome measures are ante partum
haemorrhage, umbilical cord prolapse, signs of chorioam-
nionitis (defined as fever before or during labour as a tem-
perature greater than 37,5°C on two occasion more than
one hour apart or a temperature > 38,0°C with either uter-
ine tenderness (or contractions), leucocytosis, maternal or
foetal tachycardia, or a foul-smelling vaginal discharge in
absence of any other cause of hyperpyrexia), maternal
sepsis (defined as temperature > 38.5°C and positive
blood culture or circulatory instability requiring intensive
care monitoring), thrombo-embolic complications, uri-
nary tract infection treated with antibiotics, signs of
endometritis (defined as temperature of > 38,0 °C on 2
occasions at least one our apart after the first 24 h post-
partum with associated uterine tenderness [15]), pneu-
monia, anaphylactic shock, HELLP-syndrome and death,
incidence of instrumental deliveries, maternal quality of
life, maternal intervention preference and costs. [15]
Other outcomes are direct medical and non-medical costs
generated by maternal and neonatal resource utilisation
during admission and post-discharge follow-up until 6
weeks after randomisation. The economic evaluation will
integrate the primary clinical outcome and costs in a cost-
effectiveness analysis.
Statistical analysis
Sample size
This trial is designed to demonstrate a 66% reduction of
neonatal sepsis from 7.5% in women in the expectant
group to 2.5% in women in the induction group. This
requires a total sample size of 520 patients with 80 %
power and a significance level of p = 0.05.
Data analysis
Data analysis will be performed on an intention to treat
basis and study baseline characteristics will be compared.
The relative risks and 95% confidence intervals will be cal-
culated for the relevant outcome measures. The analysis
will be stratified for centre and parity. Moreover, we will
evaluate whether the relative benefits of induction of
labour will be stronger in multiparous women and in
women with a ripe cervix at baseline.
In case of continuous data in the secondary outcome
group, t-tests will be used whereas chi-square tests will be
used if data are categorical. In case of equivalence between
outcomes, the analysis will be repeated on a par protocol
basis. Quality of life as well as pain scores will be analysed
using repeated measures analysis of variance. [16]Page 4 of 6
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ent data safety monitoring committee. A formal interim
analysis is not planned.
Ethical considerations
This study has been approved by the ethic committee of
the University Hospital Maastricht (Ref. no. MEC 05–
240). A total of about 40 academic and non-academic
hospitals have signed an intention form to participate in
the trial, most of them have started the medical ethics
committee approval procedure. Before a collaboration
clinic may start with randomisation of patients the local
ethical committee must have given their approval. The
trial is registered in the controlled clinical trial register
under number: ISRCTN29313500 [17]
Confidentially and data security
Initials of participants as well as a local patient number
are recorded in the electronic database. Linking names
with patient's numbers can only be done in the local clin-
ics. Data will be collected using Oracle Clinical Remote
Data Capture (RDC), which is a new generation of appli-
cation system that enables collection and cleanup of clin-
ical trial data using the Internet. For detailed information
on Oracle RDC, please visit the page of Oracle RDC prod-
ucts. Each participating clinic receives a login name and
password to get access to the web-secured database. The
access is restricted to the database of the clinic to which
the password and login name belongs. Full access to the
entire database is restricted to some members of the
research staff.
Discussion
Preterm prelabour rupture of membranes is still a clinical
problem in obstetric practice. Between 34 and 37 weeks
there is a lack of good clinical evidence. Induction of
labour might reduce the risks of neonatal sepsis. On the
other hand it might increase the incidence of instrumental
deliveries and neonatal respiratory distress syndrome.
This trial is designed to answer these questions in respect
to neonatal and maternal outcomes and costs-effective-
ness.
We are aware of two other studies on the subject that are
running. In Canada, a trial has been started that compares
induction of labour to expectant management in women
with PPROM. [18] This trial aims to recruit 360 women
(Safety and Efficacy Study of Intentional Delivery in
Women With Preterm and Prelabour Rupture of the Mem-
branes, Lacaze N).
In St Leonards, Australia, a trial has been recently started
similar to the trial that we have started (PPROMT – Pre-
term Prelabour Rupture Of the Membranes close to Term)
[19]. This trial aims to recruit 1812 women and has been
announced in the journal [20]. The respective investigator
groups, including ours, have planned an individual
patient data meta-analysis after completion of the trials.
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